Targeted Expression of Insulin-Like Growth Factor to Human Keratinocytes: Modification of the Autocrine Control of Keratinocyte Proliferation  by Eming, Sabine A. et al.
Targeted Expression of Insulin-Like Growth Factor 
to Human Keratinocytes: Modification of the 
Autocrine Control of Keratinocyte Proliferation 
Sabine A. Eming, Ri.chard G. Snow, Martin L. Yarmush, and Jeffrey R. Morgan 
Surgical Services, Massachusetts General Hospital and Shriners Burns Institute, Boston, Massachusetts, U.S. A. 
Somatomedin C/insulin-like growth factor-I (IGF-I) 
is required for the proliferation of keratinocytes in 
vitro. In skin, the cells known to synthesize IGF-I are 
melanocytes and fibroblasts of the dermis. To inves-
tigate the role oflGF-1 as a mediator ofkeratinocyte 
proliferation, we have used retroviral-mediated gene 
transfer to introduce the gene encoding human IGF-I 
into diploid hUlnan keratinocytes, thus causing these 
cells to produce a growth factor they normally do not 
express. Modified cells synthesized and secreted sig-
nificant levels of IGF-I (560 ng/107 cells/24 h) in vitro. 
Cells expressing IGF-I were no longer dependent on 
exogenously added IGF-I or insulin for their sus-
tained growth in Vitl'O under serum-free conditions. 
The growth of these cells did require added epider-
mal growth factor (EGF) and bovine pituitary extract. 
The addition of an antibody that neutralizes IGF-I 
inhibited cell growth, suggesting that IGF-I must be 
secreted by the cells to promote cell proliferation. To 
investigate the role of IGF-I in vivo, we grafted mod-
C IGF-I, a singl e chain polypeptide of 70 amino acids, is a m ember of the insulin-rela ted proteins, wh.ich include IGF-Il, insulin , and relaxin (Recl1.ler and Nissley, 1991). Unlike insulin, which regulates m et-abolic processes such as glucose transport, glycogen, 
and fat biosynthesis , IGF-I functions predominantl y as a mitogenic 
factor and a regulator of differentiation (Kam alati e/ ai , 1989; 
Lammers e/ ai, 1989). Significant levels of IGF-I are found in the 
plasma, and liver production of IGF-I is stimul ated by growth 
hormone . In fact , IGF-I is one of the primary m ediators of growth 
hormone ac tion (Mathews et ai, 1986) . Many other tissues produce 
IGF-I and it is thought that IGF-I may also serve as an autocrine/ 
paracrine regulator of local tissue events (D'Ercole et ai, 1984) . In 
the skin, IGF-I is produced by m elanocytes and fibroblasts but is n ot 
produced by keratinocytes, sugges ting that IGF-I m ay be a para-
crine regulator of keratinocyte proliferation (Barreca e/ ai, 1992; 
Tavakkol e/ ai, 1992). 
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ified keratinocytes expressing IGF-I onto athymic 
mice. Grafts of epithelial sheets of modified cells 
formed a stratified epithelium comparable to control 
grafts of unmodified cells. When analyzed for keratin 
16 expression and by quantitative staining for the 
nuclear proliferation antigen Ki-67, however, modi-
fied epithelia showed an increase in these markers of 
proliferation when compared with grafts of unmodi-
fied cells. This study demonstrates that genetic mod-
ification can be used to modify the autocrine control 
of keratinocyte proliferation. The de novo synthesis 
of IGF-I by keratinocytes could sustain keratinocytes 
growth itt vitro and stimulate proliferation in vivo 
without significantly altering epidermal differentia-
tion. These data further support the role oflGF-1 as a 
paracrine mediator of epidermal proliferation and as 
a potential signal of mesenchymal-epithelial interac-
tions. K ey ,vol,ds: gene t/,el'apylskin grafts. ] Invest D erma-
tol 107:113-120, 1996 
T he biologic actions of IGF-I are m ediated by high affinity 
binding to a specific cell surface receptor (Rechler and Nissley, 
1991) . IGF-I binds to the specific cell surface receptor with an 
affinity 2-3 times hig her than IGF-II and approximately 100 times 
higher than insulin. Conversely, IGF-I binds with low affini ty to the 
receptor for IGF-ll and insulin ~ In the epidennis, the receptor for 
IGF-I is expressed predomin antly by basal keratinocytes (Kran e e/ 
ai, 1991). In the hyperproliferative diso rder psoriasis , expression of 
IGF-I receptors is increased and is also found in suprabasal kerati-
nocytes (Krane et ai, 1992) . 
III "i/ro studies with serum-free cultures have demonstrated that 
IGF-I is one of a few growth £lctors required for the proliferation 
of keratinocytes. Insulin can substitute for IGF- I but only at 
concentrations that are approximately 1 DO- fold higher tlun IGF-I 
(Tavakkol e/ ai, 1992). Part of TGF-l' s action m ay be explain ed by 
it's abili ty to upregulate receptors for EGF, and it's' thought that this 
effect m ay increase the responsiveness of the cell to EGF and 
transforming growth factor-a (TGF-a), a grow th factor endog-
enou sly produced by keratinocytes (Krane e/ ai, 1991 , 1992). 
N either IGF-I nor an y other growth factor aJone is suffi cient, 
however, to promote keratinocyte clonal cell growth (Wille et ai, 
1984). IGF-l is only effective ill vitro when combined with added 
EGF or bovine pituitary extract (EPE) (Wille el ai , 1984). 
In this study, we used a gene transfer teclulOlogy to target the 
expression ofIGF-I to human keratinocytes to convert the action of 
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IGF-I from paracrine to autocrine and to study the effec ts of this 
new autocrine control ofkeratinocyte proliferation ill IIill'o as well as 
i ll vi vo . Keratinocytes expressing IGF-I were no longer dependent 
on exogenously added IGF-I or insulin for ce lJ growth ill II ilro and 
form ed a normal but slightly hyperproLiferative epidermis in villo. 
This approach provides additional data supporting IGF-I's role as an 
importa nt m ediator of hum an epidermal proliferatio n and can be 
used to elucidate the ro le of other cytokines in the skin. 
MATERlALS AND METH ODS 
Construction of Recombinant Retrovirus A cD NA encoding human 
IGF-I was inserted into the Ncol and BnmHI site of the MFG retroviral 
vector by a three-part ligation . M FG vector DNA was digested with Ncol 
and BnmI-n and gel purified. Vector DNA was ligated to two annealed 
oligonucleotides encoding the first 12 amino acids of IG F-I (5'-CATGCA-
CACCA TGTCCTCCTCGCA TCTCTTCT A-3' and 5' -CCAGGT AGAA-
GAGATGCGAGGAGGACATGGTGTG-3') and a PCR product encoding 
the remainder of the IGF- I open reading fi·ame. T he PCR product was 
synthesized using 5' -CA TCAGCCTGGCGCTGTGCCTGCTC-3' as a 
forwa rd primer and 5'-AGTCCAGGATCCTCCTACATCCTGTAGT-
TCTT-3' as a reverse primer. After PC R , the primers were removed and 
the product digested w ith EcoRlI and BnmH I and ge l purified before the 
three-part ligation . To generate a virus-producing ce ll line, M FG-I GF-I 
plasm id DNA was transfected in to a 'I'-CIUP packaging cell Une (provided 
by R. Mulfjgan , W hitehead Institute of Biomedical Research, Cambridge, 
MA) as described in Danos and Mulligan (1988). C lones of transfectants 
were isolated and screened for one producing the highest titer. 
Keratinocyte Cell Culture and Viral Infection N ormal human ke-
ratinocytes deri ved fi'om neonata l foreskins (strains A-H) were cul tured 
using a fibrob last feede r layer as p revio usly described using the method of 
H. .. h einwald and Green (1975) . Swiss mouse 3T3-J2 feeder cell s (kindly 
provided by H. Green, Harvard Medica l School) and virus-producing ce ll s 
were routinely passaged in D ulbecco's modi fied Eagle's medium (high 
glucose) (Gibco BlU, Gaithersburg, MD) , supplemented w ith 10% bovine 
ca lf serum (HyC lonc , Logan. UT ) and penicilfjn-streptom ycin (100 IU per 
ml to 100 (J.g pe r ml , Boehringer Mannheim, Indianapo lis , IN). 
Keratinocytes were genctically modified as previously described (Morgan 
el nl, 1987) . BrieRy, preconRuent primary cultures were di ssoc iated and cell s 
were passed onto mitomyc in C-trea ted virus-producing cell s. Four to six 
da ys after co-cul tivation, modified cell s were dissociated and parallel 
cul tures were prepared for protein analysis, DNA/ RNA isolation, grafting, 
and platin g effi ciency. Unmodified contro l cell s were cultured on 3T3-J 2 
cells: 
Measurement of Modified Keratinocyte Proliferation Rates To 
adjust keratinocytes to serum-free cul ture conditions, secondary cultures of 
modified and unmodifi ed cell s were washed in se rum-free medium and 
subcultured (4 X 106 cells/1 0 cm dish) in keratinocyte basa l medium (KBM, 
C lonetics) supplemcn ted with hydrocortisone (0.5 (J.g per ml), bovine 
pituitary extract (BPE, 0.4%), epiderma l growth f.1ctor (EGF, 0.1 ng per 
ml) , insulin (5 (J.g per ml) , and gentamicin-amphoteric in-B (50 (J.g per m \ to 
50 ng per ml) (MCDB 153, C lonetics, San Diego, CAl. Afte r 2 d , cell s were 
trypsinized, washed in serum-free medium and seeded at 105 cells/well per 
12-well plate or at 2 X 10' cells/well per 96-well p la te. Cells on 12-well 
plates were grown in KBM , supplemented with hydrocorti sone, B1'E, EGF 
as above, in the presence or absence of insulin (5 (J.g per ml) or recombinant 
human IGF-I (rhIGF-I) (25 ng pe r ml) (Boehringer Mannheim). To 
dctcrnline colo ny fOrJTlatioll and eel1 pro li feration, cells were fornlatin fixed 
at days 3, 6, 9, and 12 and stained with Rhodamine B (1 %) . To determine 
ifIGF-lmust be secreted and released from the cells to promote growth , we 
tested the effects of a neutrali zing antibody to IGF-l. Unmodi fied alld 
modified cell s on 96-well plates were grown in KBM, supplemented with 
hydrocortisone, BPE, EGF as above, with or without rh IGF-I (40 ng per 
ml) , respectively. Cell s were grown with or without a neutralizing antibody 
to IGF- I (100 (J.g per mI. purified mo use monoclonal an ti- human IGF- I 
antibody) (Upstate B iotechnology Inc, Lake Placid , NY) o r an unrela ted 
control rat monoclonal antibody (100 (J.g per ml) . At days 3 and 9 the cell 
dens ity was determined using a sulfo rhodamine B colo rimetric assay. Cells 
were washed with MgCI2 (1 mM) , fixed in tri chloroacetic acid (10%) (30 
mill, 4°C), sta ined with sulforhodamine B (0 .4% in glacial acetic ac id) (15 
min, room tempera ture) , and washed with Tris buffer (1 mM, pH 7.2). T he 
intracellular dye was solubili zed with T ri s buffer (10 mM , pH 7.2) and the 
o ptica l density at 570 nm was determined (THERMOmax plate reader, 
Molecular Devices, Menlo Park, CAl. 
Measurement of IGF-I Production by Modified Keratinocytes 
Modifi ed keratinocytes (10°) were plated in a 10-cm di sh (containing 10" 
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3T3 J-2 feeder cells) and grown to conRuence. Fresh medium was added (30 
ml KGM) and 1-ml samples of the culture medium were removed over a 
4-d period. Samples were brieRy centrifuged at 15,000 X g and the 
supernatant was assayed for IGF- I by radioimmune assay (Nichols Institute 
Diagnostics, San Juan Capistrano, CAl with a sensitivity of 0.3 ng per ml. 
Conditioned medium was not treated by ethanol extraction, such that only 
free IGF-I, not complexed with IGFBPs. was detected. Cells were 
trypsinized and counted , and prote in production was normalized to cell 
number. Medium conditioned by unmodifi ed keratinocytes was used as a 
c ontrol. 
Southern and Northern Blot Analysis Total genomic DNA was 
isolated from cultures of modified and control keratinocytes, digested with 
KpllI, fractionated by gel electropheresis, transferred to a nylon fi lter, and 
analyzed by Southern blot hybridization using 32P_Iabeled IGF-I probe. As 
a size standard and an estimate of the efficiency of gene transfer, 1 .5, 15, and 
150 pg of MFG-IGF-I plas mid DNA were digested along with 10 (J.g of 
control DNA and included on the Southern blot. 
Tota l cellular RNA iso lated from cul tures of modified and control 
keratinocytes by the guanidium isothiocyanate method was fractionated by 
electrophoresis in a denaturing formaldehyde-agarose ge l, blotted onto a 
nitrocellulose fi lter, and hybridi zed with a 32P-Iabeled IGF-I probe. 
Grafting of Keratinocyte Sheets C ul tures of conRuent keratinocytes 
(35 mm) (strain E-H) were washed twice with se rum-free Dulbecco 's 
modified Eagle 's medium, detached as an intact epithelium with Dispase II 
solution (1.2 U per mI , 1 h , 37°C ) (Boehringer Mannheim) and g rafted onto 
anesthetized 6-to 8-week-old athymic mice (National Institutes of Health 
Swiss N II / IIII , Taconic Farms, Germantown, NY) as described by Barrandon 
and Green (1988) . BrieRy, the detached epithelium was placed basal side up 
on a small piece of Silastic membrane (0 .005 inches thick) (Dow Corning, 
MI) and inserted under a fu ll-thiclG1ess skin Rap on the back of the mouse 
so that w hen the Ra p was closed , the basal side of the epithelium came in 
con tact with the inner side of the mouse skin . 
Histology Seven, twenty, or twenty-eight days after grafting , the human 
epithelium and subjacent mouse ti ssue were harvested for hi stologic anal-
yses. The size of the graft was measured by tracing its outline on the Silastic 
membrane and the tissue was eithe r fixed in formalin or immediately frozen 
and sto red at - 70°C until cryosectioned . Paraftln-embedded sections (5 
(J.m) were stained w ith hematoxyli n-eosin. Histologic ana lyses fro m hema-
toxylin-eosin stained grafts were made for con trol (day 7: n = '11, day 28: 
n = 2) and modifi ed (day 7: n = 13, day 28: n = 2) grafts fro m a total of 
95 mm (day 7), 6 mm (day 28) and 11 6 mm (day 7) , 14 mm (day 28) linear 
length of graft, respectively. 
Immunohistochemistry Cryostat sections (6 (J.m) fixed in acetone for 5 
min and treated with blocking so lu tion (3'1u bovine serum albumin , 1% 
normal goat se rum , in phosphate-buffe red sa line) for 1 h at room temper-
ature were incubated with a rabbi t anti-human IG-67 antibody (1 :100) 
(DAKO , Glostrup , Denmark) fo r 30 min at room temperature (control-
day 7: n = 2. day 20: n = 2; MFG-IGF-I-day 7: n = 2, day 20: n = 2' 
MFG-PDGF-A- day 7: n = 2 strains A-C) or with mouse monoclonal 
antibodies to keratins 14 , 16 (kindly provided by Dr. Irene Leigh, London 
H ospital Medical College, London , England) o r keratin 10 (1:100) (C hemi-
con International Inc., Temecula, CAl for 1 h at rOom temperature (for 
each keratin marker we stained control-day 7: n = 2, day 20: n = 2; 
MFG-IGF-I-day 7: n = 2, day 20: n = 2, stra ins A-C). To millimize 
background sta ining, sections were incubated with all affinity purifIed Fab 
fragment of goa t anti-mo use IgG (1:100) Oackson ImmunoR esearch Lab-
oratories, West Grove, PAl prior to staining with any of the mouse 
monoclonal primary antibodies. Slides were washed 4 X 15 min in 
phosphate-buffered saline. then incubated with Ruoresce in-conjugated af-
finity purified goa t anti-mouse IgG or IgM antibody (1 :50) or goat 
anti-nlbbit IgG antibody (1 :100) Oackson ImmulloR esearch Laboratories) 
for 1 h room temperature. T he slides were washed 4 X 15 min in 
phosphate-buffered sa li ne and coverslipped using 1 % n-propyl-gallate 
mounti ng so lu tion (S igma, St. Louis, M O). Antibodies were d ilu ted in 
blocking solu tion and control sections were not exposed to primary 
antibody. 
Assessmcnt of Epidermal Prolifcration T he profjferative activity of 
keratinocy tes in modifi ed and unmodified epithelia and neonata l foreskins 
was assessed by staining with a monoclonal antibody to Ki-67 , a nucleaf cell 
proliferation-associated antigen (Ando el nl, 1990; I-I ofillan-W ellenhof cl nl, 
1990). IG-67-positive cells, located in the basal or immediate ly suprabasal 
laye r, were counted fr0111 the fo llowing lengths of grafts: 17.1 mm (day 7) 
and 11.7 mm (day 20) for control grafts; 29.7 mm (day 7) and 8. 1111111 (day 
20) for IG F-I-modified grafts; 14.4 mm (day 7) for PDGF-A-modifi ed 
grafts; and 28 .3 mm for foreskin samples; these were presented'. as a 
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percentage of the total number of basal cells. Hyperproliferative edges of 
epithelial grafts were excluded. Statistical comparisons were performed 
using the Student's t test for unpajred samples. 
RESULTS 
Genetic Modification of Human Keratinocytes The struc-
true of the retroviral vector used to express the IGF-I gene in 
human keratinocytes is shown in Fig lA. A cDNA encoding 
hwnan IGF-I was inserted into the MFG vector, which was then 
transfected into the ':Jf-CIUP packaging cell line . A clone of the 
':Jf-CRIP packaging cell line producing the MFG-IGF-I recombi-
nant virus was isolated. Recombinant viruses produced by the 
':Jf- CRIP cell s are free of detectable replication-competent virus 
and have an 3mphotropic host range . 
Secondary cu ltures of human keratinocytes established from 
neonatal foreskins w ere co-cultivated with mitomycin C-treated 
':Jf-CRIP cells producing the MFG-IGF-I virus. After 4 d of 
cocu ltivation, the virus-producing cells were removed, and the 
keratinocytes were dissociated using trypsin and passed onto a 
normal 3T3 fibroblast feeder layer. 
The MFG-IGF-I recombinant genom e was detected in the 
cellular DNA of modified keratinocytes by Southern blot hybrid-
ization. Genomic DNA prepared from modified and control kera-
Mocytes was cleaved with Kp"I and transferred to a nylon mem-
brane after fractionation by gel electrophoresis. Because Kplll 
cleaves three times in the MFG-IGF-I recombinant vector, once in 
each LTR and once upstream of the IG F-I insert, it excises a 1226 
base pair fragment containing the IGF-I cDNA. Hybridization with 
32P_labeled IGF-I gene sequences revealed the presence of the 
MFG-IGF-I fragment of the correct size in the cellular DNA of 
mod.ified cells (Fig lB). When compared w ith the hybridization 
signal (:i'om 1.5, 15, and 150 pg of MFG-IGF-I plasmid DNA, it is 
clear that the modified cells contain multiple copies of the IGF-l 
gene. 
Genetically Modified Human Keratinocytes Secrete IGF-I 
Transcription of the MFG-IGF-I provirus was veri fied by northern-
blot hybridization of total RNA isolated from control and MFG-
IGF-I-transduced cells (Fig 1 C). After hybridization with 32p_ 
labeled IGF-I gene sequences, the expected transcripts fi:om the 
MFG-IGF-I provil'lls were detected in RNA isolated from modified 
cells. In accordance with previous findings, endogenous IGF-I 
mRNA was not detected in unmodified keratinocytes (Barreca et ai, 
1992; Tavakkol ef ai, 1992). 
To m easure the production of IGF-l by modified keratinocytes, 
cells were grown to confluence, fresh medium was added (30 ml), 
and portions (1 ml) of the culture medium were removed over a 4-d 
period. T he level of IGF-I was measured by radioimmunoassay. 
IGF-I was continuously secreted by modified keratinocytes up to 4 
d with an average daily secretion rate of 560 ng/l07 cells124 h (Fig 
2). IGF-I produced by modified cells was readi ly detected without 
ethanol extraction of conditioned m edium indicating that signifi-
Callt quantities of IGF-I are fi'ee and not bound to IGF-binding 
proteins (IGFBPs). Medium conditioned by unmodified keratino-
cytes did not contain any IGF-I (data not shown). 
Expression of IGF-I Modifies the Autocrine Control of 
Keratinocyte Proliferation T he growth of IGF-I-modified 
keratinocytes was determined in serum-fi'ee cul tures, w here the 
ro le of various additives is well defined . Optimal keratinocyte 
growth in MCDE 153 medium requires added EGF, hydrocorti-
sone, EPE, and insulin . If either EGF or insulin arc omitted the cells 
will not grow. T he effects of insulin arc tho ught to be partially 
mediated through the IGF-I receptor because insulin binds this 
receptor with low affInity, and a monoclonal antibody to the IGF-I 
receptor can partiaJly block the growth promoting activ ity of 
insulin (Neely ef ai, 1991). Moreover, IGF-I can substitute for 
insulin in the serum-free culture of keratinocytes (Neely ef ai, 
1991). IGF-I alone is not sufficient for keratinocyte growth and 
optimal growth requires added EGF and BPE. 
Unmodified and IGF-I-expressing cells were cultured in serum-
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Figure 1. Integration and transcription of recombinant retrovirus. 
A, proviral structure of MFG-1GF-1 recombinant retrovirus and expected 
ItNAs are diagrammed. Shown is the LTR, long terminal repeat; SD. splice 
donor; SA, sp lice acceptor; 'II +, packaging signal and sites of digestion with 
Kplll . B, Southel'l1 blot of ceBulaI' DNA (10 f.Lg) digested with KpIIl and 
probed by hybridization to a [32p] lGF_l gene sequences. Genomic DNA 
isolated from control keratinocytes (unmodjfied) (Jnlle 1) and MFG-IGF-I-
modified keratinocytes (Jnll e 2). Control DNA mixed with MFG-IGF-I 
plasmid DNA 1.5, 15. and 150 pg (lnlle.< 3. 4. and 5. respectively). Shown 
are size markers. C, northern blot of total RNA (5 f.Lg) isolated from control 
(lnll e 1) and MFG-IGF-I-transduced keratinocytes (lnll e 2). Filter was 
hybridized with a [32p] IGF_1 probe. Shown are the rRNA markers. 
free medium with or without insulin or rhIGF-I. At days 3, 6, 9, and 
12, the cell s were fixed and stained (Fig 3). Unmodified keratino-
cytes showed little or no growth in the absence of insutin or 
rhIGF-I. As an additional control for the effects of genetic modifi-
cation, we tested cells that were modified to express PDGF-A, a 
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Figure 2 . Modified keratinocytes secrete IGF-I. A time course of 
IGF-I secretion was determined by removing portions of the culture 
medium of a confluent culture of modified keratinocytes as indicated over 
a 4-d period and, IGF-I was measured by radioimmunoassay. 
cytokine that does not stimulate keratinocyte proliferation. Like 
unmodified celis, PDGF-A-expressing cells showed little or no 
growth in the absence of insulin or rhIGF-I. In contrast to these 
controls, modified keratinocytes expressing IGF-I were able to 
form colonies and proliferate in the absence of insulin or rhIGF-l. 
[n fact, colony forming efficiency and proliferation of IGF-I-
expressing keratinocytes were comparable to cells cultured in the 
presence of insulin (5 fLg per ml) or rhIGF-I (25 ng per ml). 
To determine if IGF-I must be secreted and released from the 
cells to promote growth, we tested the effects of a neutralizing 
antibody to IGF- l. Unmodified and IGF-I-expressing keratinocytes 
were grown in the presence or absence of a neutralizing antibody to 
IGF-I with or without added IGF-l. At days 3 and 9, the cell density 
for these conditions was determined using a colorimetric assay. At 
both time points, growth of unmodified keratinocytes in the 
presence of added rhIGF-I could be inhibited by the neutralizing 
antibody to IGF-I (Fig 4). Likewise, growth of keratinocytes 
expressing IGF-I and cultured in the absence of added rhIGF-I 
could be significantly inhibited by addition of the neutralizing 
antibody (Fig 4). T hese data further confirm that the new autocrine 
growth control of the modified cells is mediated by IGF-I and that 
because its action can be inhibited by a n eutralizing anti body, IGF-I 
must be secreted to promote growth. Exposure of cells to an 
unrelated control rat monoclonal antibody did not affect cell 
growth (data not shown). 
Keratinocytes Expressing IGF-I Form a Stratified Epithe-
lium When Transplanted to Athymic Mice Keratinocytes 
secreting IGF-I were tested for theif ability to form an epidermis 
when transplanted to athymic mice. N ormal or modified keratino-
cytes were grown to confluence in a 35-mm dish. The cells were 
treated with Dispase, detached as an epithelial sheet, and grafted 
onto the underside of a dorsal skin flap. The basal side of the sheet 
was placed directly on the epimysium of the molise panniculus 
carnoslls. Seven and twenty-eight days after grafting the human 
epithelium and the subj acent mouse tissue, the sheets were fixed 
Bnd stained. 
Both unmodified cells and cells expressing IGF-I developed a 
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Figure 3. Expression of IGF-I by keratillocytes modifies the auto-
crine control of keratinocyte proliferation. Unmodified , IGF-I, or 
PDGF-A-modiiied keratinocytes were grown in serum-free medium, with 
or without insu lin or rhIGF-l. At indicated time points cul tures were fixed 
and stained with Rhodaminc B . 
stratified epidermal stru cture consisting of stratum basale , spino-
sum, granulosul11, and corneu;ll , indicating complete terminal 
differentiation. Seven days after g rafting, the epithelia of modified 
and unillodified cells were several ce ll layers thick (Fig 5A,B) . 
Twenty- eight days after grafting, the thickness of both epithelia 
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Figure 4. Bioactivity of IGP-I released frOI11 modified keratmo-
cytes can be blocked by an IGF-I neutralizing antibody. Unmoclified 
and MFG-IGF-I-modifi ed kcratinocytes were grown in serum-free mcdium 
in the presencc or absence ofrhl GF-I (40 ng per m l). To block the effect of 
IGF-I on growth, cells were grown in the presence or absence of 3 
neutralizing antibody to IGF- I. At indicated time points cells were fixed and 
cell numbers determined using a colorimetric assay. 
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A B 
Figure 5. IGF-I-secreting keratinocytes form a stratified epidteliulll when transplanted to athymic mice. Cultures of confluent epithelia 
generatcd from unmodified (A, C) or MFG-IGF-I-modified keratinocytes (B, D) were detached from thc dish with Dispase trcatment and graftcd under a 
full thickncss skin flap of athymic mice. Sevcn (A, B) and 28 (C, D) days la te r the grafts werc fixed, and paraffin-cmbeddcd sections (5 f.Lm) wcre stained 
with hcmato:\,yIin and eosin . lt c, human epidermis; ct , connective tissue; pc, panniculus carnosus (bar, 100 f.Lm). 
were diminished with fewer cells in the stratum spinosum and 
granulosum, compared with day 7 after grafting (Fig 5C,D). 
Overall, the morphologies of the epidermis form ed by contro l and 
IGF-I-expressing keratiJlocytes were indistinguishable at both time 
points. In th.is grafting model, the epithelial graft is placed subder-
mally and the cornified layer does not exfoliate; thus, the thickness 
of the stratum corncum increases with time. 
The connective tissues that formed subjacent to grafts of IGF-I-
expressing cells and unmodified cells were also similar. At day 7, 
the tissue subjacent to control and IGF-I-expressing grafts was a 
loose connective tissue, containing fibroblasts and occasional 
mononuclear cells. Within this connective tissue were uniformly 
distributed fibers oriented parallel to the overlying epidermis. At 
day 28, the connective tissue adjacent to modifi ed and unmodified 
epithe lia decreased slightly in cellularity and the collagen fibers 
appeared thicker and more dense, compared with day 7. No 
difference in cellu larity, vascularity, or thickness of the cOlUlective 
tissue was evident between modified and unmodified grafts. These 
results are in contrast to our previous data with grafts expressing 
PDGF-A in which the subjacent connective tissue was significantly 
thicker, more cellular, and highly vascularized compa.red with 
control grafts (Eming ct ai, 1995). 
Markers of Proliferation Are Elevated in IGF-I-Expressing 
Grafts To determine whether keratin expression was altered in 
grafts of IGF-I-expressing keratinocytes, we stained sections of 
modified and unmodifi ed epithelia, as well as normal neonatal 
foreskin wi til monoclonal antibodies specific for keratins 1/10 
(KI/IO), 14 (K14), and 16 (KI6) . In normal epidermis, KI4 is 
synthesized in the basal layer (Purkis ct ai, 1990) and KI/IO are 
expressed in suprabasal layers (Weiss et ai, 1984). In hyperprolif-
erative skin diseases such as psoriasis, K14 expression often extends 
to the suprabasal layers , and a new keratin, K16, is induced in the 
diffe rentiating cells (Weiss et ai, 1984) . 
In the epidermis of the n eonatal foreskin, staining for K14 was 
confined exclusively to the basal layer, whereas staining for KI and 
KIO was observed only in suprabasallayers, and no staining for K16 
was evident (data not shown). Seven days after grafting, modified 
and unmodified epithe lia showed comparable strong staining for 
KI4 tlU'oughout the entire epithelium (Fig 6A-B) and staining for 
KIO in the suprabasal layers (Fig 6C-D) . In contrast, K16 sta.illing 
was weak in supra basal layers of control grafts and strong in 
IGF-I-modified grafts (Fig 6E,F). Staining for K14, Ki0, and K16 
at day 20 for control and modified epithelia was decreased w hen 
compared with day 7 afte r grafting. Suprabasal staining for K16 in 
IGF-I-modifi ed grafts remained stronger, however, compared with 
unmodified g rafts at this time (data not shown). Collectively, the 
keratin staining pattern at 7 and 20 d postgrafting by modified and 
unmodified epithelia were similar to those described for a regen-
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Figure 6. K16 expression is elevated in IGF-I-overexpressing epithelium. Unmodified (A, C, E) and IGF-I-modifi ed (B, D, F) epithelia were 
tra nsplanted to athymic mice. At day 7, gra fts were frozen , and cryosections were stained using mo use monoclonal antibodies to K1 4 (A, B) , Kl0 (C, D) , 
and K16 (E, F) . Staining was vi suali zed with a Auorescein-conjugated affinity-purificd goat-an ti-mo use IgG antibod y. lie, human epidermis; cl , connective 
tiss uc (bnr, 100 /Lm). 
e rative epidermis. Compared w ith contro ls, the e ffects of IGF-I 
expression were evident only as an increase in K16 expression. 
As a further tes t for proliferation ;11 11;110, w e stained tissue section s 
from bio psies at 7 and 20 d after grafting, with a monoclonal 
antibody to Ki-67, a nuclear antigen associated with cell prolifer-
ation . T he Ki-67 antigen is present in the nucl ei of cells in late G1, 
S, G2, and M phases, but is absent from the GO and the early Gl 
phases (Ando el nl, 1990; Hofm an-Wellenhof e/ til , 1990). Epithelia 
derived from IGF-I-expressing cells had signifi cantly increased 
numbers of Ki-67-positive cells at 7 and 20 d after grafting 
compared with grafts of ulUTIodified cells, grafts of cells expressing 
PDGF-A, or neonatal foreskin (Table I). On average, IGF-l-
expressing grafts had a 2-fold increase (day 7) or a 4-fold in crease 
(day 20) in Ki-67-positive ce ll s, when compared with control 
epithelia (Table I). The Ki-67-positive cells of unmodifi ed and 
PDGF-A-expressing epithelia we re predominantly in the basal 
layer, with few positive cells in the suprabasal layer. In contrast, 
IGF-I-expressing epithelia had increased numbers ofKi-67-positive 
cells in the basa l layer as well as significant numbers of positive cell s 
in the supra basa l layer. 
DISCUSSION 
In this study we investigated th e ;11 11 ;11"0 and ;11 11 ;110 e ffects of altering 
the autocrine growth control of human keratinocytes. Human 
diploid keratinocytes were genetica ll y modifi ed by retroviral-
mediated gene transfer to express IGF-I, an important mitogen for 
keratinocytes and a cytokine they normally do not express . Modi-
fied cell s synth esized IGF-I at levels up to 560 ng/107 cells124 h. 
When grown in serum-free cu ltures, IGF-I-expressing cells no 
longer requ ired added IGF-I or insulin, thu s demonstrating tha t 
genetic m odification had engineered a new autocrine control for 
these cells. Neutra lizing antibody to IGF-I inhibited the growth of 
the cell s indicating that IGF-I autocrine control of these cells 
required secretion of IGF-I. 
Our findings are consistent with earlie r work that demonstrated 
the strict requirem ent for IGF- I or high-dose insulin for the growth 
of human keratinocytes in serum- free culture (Will e et til, 1984). 
T hese studies also showed that IGF-I alone was not sufficient for 
keratinocyte g rowth and that optimal growth required added EGF 
and BPE. Likewise, our IGF-I-secre ting cells w ere also sti ll depen-
dent on added EGF and BPE for growth , suggesting that this new 
autocrine control of keratinocytes was selective for IGF-I and that 
the growth requirements of the cells had not been grossly altered. 
It also sugges ts that although IGF-I can upregulate EGF receptor! 
ligand levels, dlis effect is not enough to obviate the need for added 
EGF to promote growth (Krane el ti l, 1991 ; Vardy el til , 1995). 
In many cell types, the action of IGF-I appears to be controlled 
Table I. Proliferation of IGF-I-Expressing Keratinocytes 
111 Villo 
Ki67-positivc cells Length of graft 
Strains l l Day" ('Yt,) ( :!: SEM)' (111111 2) 
Control 
A 7 13 .9 (:!: 6.7) 8 .1 
B 7 14 (:!:8. 2) 9.0 
C #1 20 10.4 (:!: 3.9) 5.4 
C #2 20 10.7 (:!: 3 .0) 6.3 
MFG-PDGF-A 
A 7 8 .6 (:!: 5.6) 5.4 
B 7 10.0 (:!: 2 .8) 9.0 
MFG-IGF- l 
A 7 33 .9" (:!: 15.3) 19.8 
B 7 20.45" (:!: 6.2) 9.9 
C #1 20 43 .75" ( :!: 11.3) 3.6 
C #2 20 34.38" ( :!: 14.7) 4.5 
N eonata l foreskin 11 .0 (:!: 3 .6) 28.3 
./ Epidermal grafts were made of hum,lIl epidermis generated from unmodified or 
MI' G- IGF-I-transduccd kcratinocytes. 
IJ Epiderm:!1 g rafts we re harvested 7 and 20 d aftcr grafting. 
r Activa tion of ccUuJar pro liferatio n \V.I S quantitated by the counting ofkeratinocyrcs 
expressing Ki67 + nuclei located in the b:1 sal or immediately suprabasn\ la yer and 
presented as a perce ntage of basal cells per fie ld of view. 
"p < 0.05. 
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by IGF-binding proteins (IGFBPs-1 to -6) , which modulate the 
interaction of IGF-T w ith its receptor (Clemmons, 1992). Most ill 
vitro data demonstrate that the complex of IGF-I with its binding 
protein is not recognized by the receptor and hence is biolog icaUy 
inactive. Conversely, there is evidence that certain IGF-l-binding 
proteins, such as IGFBP-1 and -3, have both inhibitory and 
stimulatory efFects on IGF-I actions, depending on the experimental 
condition (De Mellow and Baxter, 1988; Tsuboi el ai, 1995) . In the 
skin, de rmal fibroblasts produce IGFBPs -3 , -4 , -5 , and -6; and 
recently, it has been shown that human ke ratinocytes synthesize 
IGFBPs -2 , -3, -4, and -6 (Murashita el ai, 1995) . One study 
suggests that keratinocyte produced IGFBPs may modulate kerati-
nocyte responsiveness to JGF-l. They showed that a mutant form of 
IGF-I that doesn't bind IGFBPs was a more potent mitogen for 
keratinocytes i/l. vilro than normal IGF-I (Wraight cl ai, 1994). In 
our system, JGF-I produced by modifi ed cell s was readily detected 
without the need for ethanol extraction of conditioned medium to 
separate IGF-l fi'om its IGFBPs, indicating tha t significant quantities 
of IGF-J were free and not complexed with IGFBPs . Moreover, 
keratinocytes producing IGF-I w ere no longer dependent on added 
IGF-I for growth ill IIitro demon strating that IGF-I synthesized by 
modified cells was biologica lly active. T hus, if IGF-I synthesized by 
modified keratinocytes is complexed with keratinocyte produced 
IGFBPs, there is sufficient free IGF-I produced by modifi ed cells to 
be detected by radioimmune assay and to act as an autocrine 
stimulator of keratinocyte growth . 
One of the advantages of using retroviral-mediated gene transfer 
to genetically modify cell s is that the gene is stably in tegrated and 
the effects of genetic modification can be e valuated ill vitro as well 
as ill IIillo by transplantation of a transgenic epithelium . In this way, 
the effects of new autocrine con tro ls on the g rowth and difFe ren-
tiation of the modified tissue can be examined , as well as the effects 
o n adjacent neighboring tissues. Kel'atinocytes expressin g TGF-I 
were grafted as an epithe lial sheet to athymic mice wherein control 
unmodified cell s and cells secreting IGF-I formed comparable 
stratified epithe lia. Both epidermal structures were several cell 
layers thick complete with stratum granulosum and corneum . Slight 
di.fferen ces were seen when the grafts were stained for kerati n gene 
expression. Seven days after g raftin g, the IGF- I-secreting tissue had 
increased staining for keratin 16, a marker for regenerative epithe-
lium . More dramatic was the increase in the number of proliferating 
cells in the IGF-I epithelium ve rsus the control epithelia. T he 
number of Ki-67-positive ceUs in the basa l and supra basa l layers of 
IGF-I grafts was signifi cantly increased over controls at 7 and 20 d 
after grafting. N everthe less, this increase in proportion of prolifer-
ating cells did not grossly alter keratinocyte growth and differenti-
ation ill IIillO. The in crease in prolife rating cell s could be balanced by 
an increase in the rate of terminal d ifferentiation. T hus, e levated 
levels of IGF-I may be necessary for an in crease in the proliferation 
of the epidermis, but hig h levels of IGF-I alone are not sufl'icient to 
cause gross alterations of the epidermis as seen in the hyperprolif-
erative disorder , psoriasis. 
Transgen.ic mi ce in which cytokine overexpression has been 
directed to the epidermis have been used to address similar 
ques tion s rega rding autocrine/paracrine growth control of the 
epidermis. When the gene encoding TGF-a, a cytokine endog-
enously made by keratinocytes, was linked to a keratin promoter 
and overexpressed in the stratified sq uamous e pithelia of transgenic 
m.ice, prolife ration of basal keratinocytes was en hanced and epide r-
mal th ickening persisted for 2 weeks afte r birth (Vassar and Fuchs, 
1991) . When the gene encoding keratinocyte growth facto r, a 
cytokine not produced by keratinocytes (norma lly produced by 
derm al fibrob lasts), was expressed usin g the keratin promoter, the 
transgenic mi ce also had a th ickened epidermis that persisted for 4 
mo (Guo et ai, 1993) . T hese studies suggest that TGF-a and 
keratinocyte growth factor are important autocrine and pal'acrin e 
mediators of epidermal homeostasis, respectively. As in o ur l'esu lts 
with IGF-I , however, overexpression of neither cytokine alone was 
sufficient to sustain prolonged hyperproliferation of th e epidermis. 
The approach used in o ur study can serve as an alte rnate m ethod 
for generating animals with a transgenic epithe lium and can be used 
to ask similar questions of the human e pidenllis. One aspect of the 
need for alten1ate ill lIivo models is evident fi'om two recent reports 
of mice with targe ted disruptio ns of the gene encoding tlle receptor 
for EGF (Sibilia and Wagne r, 1995; T hreadgill ct ai, 1995). T he 
phenotype of these EGF receptor knockout mice was highly 
dependent o n the gene tic backgro und of th e strain of mice used. 
On one genetic background homozygous muta.nts died ill IItero 
beca use of defects in the placenta, wh ereas mutants in a d ifFerent 
genetic backg round surv ived for up to 3 weeks and had de fects in 
the skin a.nd other organ systems . 
In our grafting mode l, a connective tissue forms adjacent to the 
grafted epithelium. T hus, w e are able to determin e not o nly the 
amocrine ac tions of an overexpressed cytokine, but also its para-
crine effects on the adjacent tissue. In a previous report, we showed 
that the connective tissue subj acent to grafts overexpressing 
PDGF-A w as significantly thicker , m o re cellular, and more vascular 
than controls 7 d afte r grafting (Em ing et ai, 1995). IGF-I has 
numero us efFects on connective tissue cells ill lIitro . It stim ul ates 
proli feration of fibroblasts and their production of collagen type I 
and is chemotac tic and mitogenic for endothelial cells (Grant cf ai, 
1987; Granot ct ai, 1991; Bar ct ai, 1988). Yet, in the present study, 
the connective tissues formed adjacen t to the control and IGF-I-
expressing epithelium w ere comparabl e with no gross differen ces in 
thickness , cellularity, or vascularity. 
Several factors cou.ld inAuence IGF-T's effect on connective tissue 
ill I, i IlO . The host supply oflGF-I in connective tissue may not be a 
limiting factor, or dermal- and epidermal-derived IGFBPs could 
interact with the keratinocyte-produced IGF-T and modulate its 
paracrine action on the connective tissue . Alternatively, TGF-I m ay 
not have the activities of PDG F that stimulate connective tissue 
formation in this model, such as PDGF's abi li ty to be chemotactic 
for neutrophils , m acrophages, and fibroblasts. Lastly, IGF-I may 
have a more prominent role in regulating the epidermis rather than 
the de rmis. Mice with a targe ted disruption of the typ e I IGF-I 
receptor have a relatively unaffected dermis, w hereas epidermal 
developm ent and hair morphogenesis w ere severely affected with 
few spinous keratinocytes and premature ep ide rmal differenti ation 
(Liu et ai , 1993). 
IGF-I may be useful for cutaneous tissue repair. IGF-T has been 
de tected in human wound Auid and its e"-'jJressio n is e levated in 
granulation tissue after injury of the skin (Steenfos and Jansson, 
1992). Top ical applica tion of recombin ant IGF-T simultaneous with 
PDGF in an imal studies resu lts in accelerated cutaneous tissue 
repai,r, and systemic administration of recombinant human growth 
ho rmone to patients w ith severe bums elevated their reduced IGF-I 
serum levels and accelerated re-epithelialization of partial thi ckness 
wounds (Lyn ch el ai , 1987; Gore et ai , 1991; Gilpin eI ai, 1994) . One 
limi tation of the systemic admini stration of growth hormone is its 
diabetogenic properties. Cultured grafts expressing JGF-I m ay be 
useful for the loca.! synthesis and delivcl), of IGF-I in an TGF-I-
de fi cient conditio n . 
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